All Psychedelic Trials

This page displays all psychedelic trials in Blossom’s database in one list.

To use all the search functionalities available on Blossom, see our Psychedelic Trials Search page.

Or navigate to one of our other databases | Courses Search (List) | Books Search (List) | People Search (List) | Companies Search (List) | Papers Search (List) | Videos Search (List) | Measures Search (List) | Events Search (List) | Compounds Overview (List) | Topics Overview (List) | Countries Overview (List)

All Psychedelic Research Papers List

• Understanding Neuroplasticity Induced by TrYptamines (UNITy): the effects of dimethyltryptamine (DMT) on drinking
• A study carried out on healthy volunteers to understand how COMP360 can be taken in a safe and well-tolerated way
• Safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and effects of intravenous (IV) and intramuscular (IM) dosing of SPL028 (deuterated DMT fumarate [a serotonergic psychedelic]) in healthy volunteers and participants with major depressive disorder (MDD)
• Pilot Study of RR-HNK in OCD ((HNKO))
• Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression (KAP)
• Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy (PAP_OXT)
• Optimizing Microdosing and Meditation (OMM)
• A Study of a Psilocybin Analog (CYB003) in Humans With Major Depressive Disorder (APPROACH)
• Psychedelic Virtual Reality
• Ketamine Therapy for Methamphetamine Use Disorder & HIV (KetaMet)
• MDMA-Assisted Therapy for Pathological Narcissism
• A study on the safety, tolerability, and effects of GM-2505
• Ketamine-assisted psychological therapy to reduce alcohol relapse
• Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
• Cognitive Training as an Adjunct to Ketamine in Real-world Clinics
• Early Effects of Ketamine vs Placebo With Venlafaxine in Severe Depression Patients (MOODBOOSTER)
• Ketamine for Methamphetamine Use Disorder (KMD)
• IV Ketamine Vs. in Esketamine for MDD TRD
• Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND) (TRANSCEND)
• Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST) (SYNVEST)
• Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression (Psilo-BD)
• Investigation to Understand and Optimize Psilocybin (OPTIMIZE)
• Effects of Psilocybin on Shared Experience
• Pharmacology of human decision making – Study of the effects of ketamine on healthy volunteers (18-55) making simple perceptual decisions
• Does psilocybin alter the brain’s response to food choice and reward?
• Ketamine-assisted psychotherapy for methamphetamine use disorder
• Pilot investigation of psychedelic-assisted psychotherapy for treatment of post-traumatic stress disorder (PTSD) in people diagnosed with co-occurring borderline personality disorder – a controlled before-and-after study
• Pilot study of administration of psilocybin in healthy volunteers within a marae setting
• Feasibility study testing the protocol of single dose of psilocybin given to people who have had little improvements with brief psychological intervention
• Mechanistic Studies of Psilocybin in Headache Disorders
• Open-Label Psilocybin
• Psilocybin-assisted Therapy for Alcohol Use Disorder
• The Kite Trial: Examining the Effectiveness of Ketamine for Adults with Bipolar Depression
• Safety for Home Administration of Microdose Psilocybin Use
• Psychedelic-assisted Group Program for First Responders
• Psilocybin Therapy for Depression in Parkinson’s Disease (PDP2)
• Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression
• i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial (Ket-CBT)
• Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought
• Psilocybin versus ketamine – fast acting antidepressant strategies in treatment-resistant depression
• The Impact of Psilocybin on Pain in Fibromyalgia Patients and Healthy Volunteers: a Multicenter Trial
• Ketamine in treatment-resistant major depression
• A 24-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults with Alcohol Use Disorder (AUD)
• Efficacy and feasibility of intranasal ketamine on acute suicidality, a double blind randomized placebo-controlled trial (Ketamine Trial for Acute suicidality, KETA)
• Intravenous ketamine for Treatment Resistant Depression: Exploring biomarkers of response and relapse A double-blind, randomized controlled trial
• A pilot study on oral s-ketamine for depression and demoralization in patients with advanced cancer receiving palliative care
• Pharmacologic treatment augmentation in chronic depressionrandomized, controlled, double blinded, phase II study
• A multicentre, double-blind, randomised, placebo-controlled phase II trial with a 3 week treatment period to assess the efficacy, safety and tolerability of add-on treatment with Ketamine hydrochloride prolonged release tablets (KET01, 120 mg or 240 mg once daily) in outpatients with treatment resistant depression
• Brain Injury and Ketamine: a prospective, randomized controlled double blind clinical trial to study the effects of ketamine on Therapy Intensity Level and intracranial pressure in acute brain injury patients.
• Ketamine augmentation of ECT to improve outcomes in depression
• A Preliminary Study of Intravenous Ketamine in Selective Serotonin Reuptake Inhibitor (SSRI)-Resistant Depression
• Efficacy of Ketamine for the Prevention of Relapse in Patients with Opioid-Use Disorders (OUD)
• A phase I, multi-centre, double-blind, placebo-controlled parallel group study to assess the pharmacoMRI effects of AZD6765 in male and female patients fulfilling the criteria for Major Depressive Disorder
• Ketamine as an Adjunctive Therapy for Major Depression (2) (KARMA-Dep2)
• A multicentre, double-blind, randomised, placebo – controlled phase II study to assess efficacy, safety and pharmacokinetics of inhaled Esketamine in subjects with treatment-resistant bipolar depression
• Ketamine for the treatment of depressive and negative symptoms in patients with schizophrenia: a randomized controlled cross-over pilot study
• The effect of intranasal ketamine on suicidality in severely depressed and suicidal patients. Randomized, placebo-controlled study
• Subcutaneous ketamine infusion in palliative care patients with advanced life limiting illnesses for major depressive disorder: A phase II pilot feasibility study
• Pilot study on the effects of ketamine on mood and eating disorder cognitions in enduring anorexia nervosa
• Pilot study evaluating the efficacy of subcutaneous ketamine for the treatment of depression in the elderly
• A multi-center, randomized, subject and investigator-blinded, placebo-controlled, active comparator, parallel-group proof of concept study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of MIJ821 in patients with treatment-resistant depression
• A randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy, safety, tolerability, and pharmacokinetics of single subcutaneous MIJ821 injection in addition to standard of care in participants with treatment-resistant depression
• The role of CYP2D6 in the pharmacokinetics of ibogaine in healthy volunteers
• Effects of low dose intramuscular ketamine on depression ratings in depressed patients with cancer in palliative care
• Pilot study for the rapid alleviation of depression in depressed alcohol dependent persons using ketamine
• Can memantine prevent memory impairment induced by MDMA in humans
• MDMA and prosocial behavior
• Evaluating the efficacy of psilocybin-assisted psychotherapy in treatment resistant depression (EMPACT): A randomised, double blinded, 4 arm parallel adaptive trial
• Ketamine Therapy Experiential Education Study
• A Randomized Neuroimaging Trial of Psilocybin in Depression
• Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication
• Evaluation of Psilocybin-Assisted Psychotherapy in Treating Severe Depression in Patients With PTSD
• Ketamine to Treat Patients With Post-comatose Disorders of Consciousness
• Psilocybin-assisted Therapy for Phantom Limb Pain
• Psilocybin rTMS for Treatment Resistant Depression
• Northwest Therapies Trauma Psilocybin Study Compassionate Use Study
• Effects of Subanesthetic Dose of Ketamine Given on Postoperative Mood in Patients Undergoing Fractional Curettage
• Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder
• Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)
• Effect of Psychedelic VR-augmented Therapy on Patients With Clinical Depression
• Safety Profile of Psilocybin for Cocaine Use Disorder
• Conscious Dying/Conscious Living: Ketamine-Assisted Psychotherapy
• A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental Health
• Effect of Intravenous S-ketamine on Opioid Consumption
• Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder
• Does Psilocybin Change Synaptic Density in Amnestic Mild Cognitive Impairment
• Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
• Brain Network Dynamics of Depression During Esketamine Treatment
• Repeated Intranasal Esketamine Plus Almond Therapy in Patients With Treatment Resistant Depression (ZYL-730-01)
• ESKETamine for FIBromyalgia Treatment
• Dose Optimization of MDMA-Assisted Therapy for PTSD (DosOp)
• Psilocybin vs Ketamine for Alcohol Use Disorder (Psi vs Ket)
• A Study of Psilocybin for PTSD (PSI-3PO)
• Ketamine HCl Prolonged Release Oral Tablets for CRPS
• Study of Psilocybin for Anorexia in Young Adults (SPANYA)
• Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer
• A Phase 1b Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence
• Ketamine for Sedation in Severe Traumatic Brain Injury (Ketamine)
• Ketamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression
• The Effect of Outpatient Ketamine Infusion on Chronic Neuropathic Pain and PTSD
• A Phase 1, Open-label, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of a Single Intravenous Infusion of TRP-8803 (Psilocin) in Healthy Adult Participants
• Treatment of Suicidal Ideation in the Emergency Department Using Nitrous Oxide (PROTORISC)
• Pharmacologic Treatment Augmentation in Chronic Depression (Ket+CBASP)
• Behavioural Activation Therapy and Esketamine for Resistant Depression
• (GluEsk) Glutamate and Esketamine (GluEsk)
• Psilocybin – a strategy of rapid antidepressant response in depression comorbid with cancer, a randomized double-blind study with the possibility of entering open extension
• Efficacy and tolerability of psilocybin-assisted physiotherapy on motor symptoms in refractory Functional Neurological Disorder
• A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single, Ascending, Subcutaneous Doses of FT-104 HCl In Healthy Volunteers Safety, Tolerability, and Pharmacokinetics of Subcutaneous FT-104 HCl (SAIL-101)
• Safety, tolerability, and feasibility of psilocybin-facilitated treatment for methamphetamine use disorder: A pilot study (Psi-MA): A pilot study (Psi-MA)
• Active-controlled trial of a Ketamine Assisted Group Mindfulness intervention for Alcohol Use Disorder
• Low-dose Ketamine Infusion Among Adolescents With Treatment-resistant Depression
• Intranasal Ketamine in Ultra-REsistant Depression (SURE-ECT Non Responders) (SURE-ECT)
• Open-Label Dose-Ranging Study of Oral SM-001 in Healthy Adults
• Phase 2 Clinical Trial of GH001 in Postpartum Depression
• Acute Effects of 3,4-methylenedioxymethamphetamine (MDMA) With and Without a Booster Dose
• Pairing Psilocybin With Transauricular Vagus Nerve Stimulation (ENHANCE)
• A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Major Depressive Disorder With One Prior Treatment Failure
• MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study) (MDMA-CBT4OCD)
• MDMA-assisted Prolonged Exposure Therapy for Comorbid Alcohol Use Disorder and Post-traumatic Stress Disorder (MPATHY)
• A pilot study testing the feasibility of a single microdose of ayahuasca alkaloids on neurotransmitters, inflammation marker levels, safety, and mood in healthy adult volunteers
• Ketamine-Assisted PsychoTherapy ViAbility in Treating Cancer-related Emotional Distress
• Positioning of Esketamine Treatment in the Real-world Management of Depression
• The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)
• Ketamine Treatment Plans for Chronic Conditions
• Predictors of Intravenous Ketamine Response in TRD
• Connectivity Changes Associated With Ketamine Assisted Psychotherapy for PTSD
• Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department
• Ketamine & Crisis Response Plan for Suicidal Ideation in the ED
• Ketamine + Mindfulness for Depression
• Effect of Esketamine on Reducing Postoperative Anxiety and Depression in Adolescent Patients
• Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine
• Ketamine for OUD and Comorbid Depression (OUDCD)
• A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment
• Phenomenological Explorations of the Esketamine-Induced Transient Dissociative State
• Intravenous Esketamine on Prevention of Postoperative Depression in Patients Undergoing Cardiac Surgery
• Ketamine for Treatment-Resistant Bipolar Disorder
• Effect of Low-dose Esketamine on Maternal Depression at 2 Years After Childbirth
• The Effects of Low Dose Ketamine on Cardiovascular Function
• Observation of Ketamine Treatment Safety and Tolerability in Adult Psychiatry Clinic Medical University of Gdańsk Inpatients
• Combined Ketamine and eCBT Intervention for PTSD
• Synaptic Imaging and Network Activity in Treatment Resistant Depression (SIGNATURE)
• A Study of Ketamine Infusions to Treat Clinically-depressed ICU Patients
• Ketamine and Motivational Enhancement Therapy for the Treatment of Tobacco Use Disorder
• Ketamine + Magnesium for Chronic Cluster Headache (KETALGIA)
• Ketamine Treatment of Youth Suicide Attempters
• Open Study of the Neurobiological Effects of Intranasal Ketamine in Children and Adults With Bipolar Disorder
• Ketamine for OUD and Suicidal Ideation in the ED
• Prediction of REsponse to Depression Interventions Using Clinical and TD-fNIRS Measurements (PREDICT)
• The Effects of Ketamine and Methadone on Postoperative Pain for Laminectomy
• A Study to Evaluate Ketamine for the Treatment of Rett Syndrome
• Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide
• Characterization of Altered Waking States of Consciousness in Healthy Humans
• Ketamine for Combined Depression and Alcohol Use Disorder (KeDA)
• Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial (K-PASS)
• [11C]-(R)-Rolipram to Measure cAMP Signaling Before and After Ketamine
• Perioperative Ketamine in Opioid-Tolerant Patients Undergoing Lumbar Spine Surgery
• A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression (SUSTAIN-3)
• A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine
• The CHECK Trial: A Comparison of Headache Treatment in the Emergency Department: Compazine Versus Ketamine (Check)
• An Efficacy and Safety of Proprietary Formulations of Oral Ketamine + Aspirin in Treatment of Acute Headache
• Mindfulness-assisted Psychedelic Therapy (MAPT)
• Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin (PSI-1V2)
• Molecular Imaging Study of Harmine/​DMT: a Basic Research Approach (HaD-PET)
• Psilocybin-Assisted Therapy in Treatment-Resistant Depression
• Psilocybin for Hospitalized Patients With Treatment-resistant Depression (PSIHOS-D)
• Psilocybin in Alcohol Use Disorder With Comorbid Depression (PAD)
• Low-Income Group Psilocybin Assisted Therapy for Depression (LIGPATD)
• Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD (PAP-OCD)
• Psilocybin for Major Depressive Disorder (MDD) (uAspire)
• MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents
• Examining 3,4-methylenedioxymethamphetamine (MDMA) Effects on Psychological, Relational and Hyperarousal-Related Neural Reactivity Mechanisms in Veterans With PTSD and Moral Injury
• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 in Healthy Participants
• Effectiveness of Ketamine Treatment for Three Consecutive Days in Depression
• MDMA and prosocial behavior: The role of the 2a-serotonin receptor
• Ketamine-Assisted Mindfulness-Based Cognitive Therapy for Depression: A Pilot Study
• Ketamine Treatment for PTSD and MDD in TBI
• Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression
• Auditory MMN EEG in TRD in Response to Ketamine
• A Phase 1, Open-label, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of a Single Intravenous Infusion of TRP-8803 (Psilocin) in Healthy Adult Participants
• A Phase 2b double-blind, randomized, low-dose comparator-controlled clinical trial to assess the efficacy and safety of PEX010 in psilocybin-assisted psychotherapy for the treatment of adjustment disorder due to incurable cancer diagnosis
• Toward Embodied Healing: Feasibility of a Psilocybin-Assisted Psychotherapy for Partially Recovered Anorexia Nervosa and Persistent Body Image Disturbance. A Manualised, Three-Dose, Open-Label Case Study
• Assessing the effects of Lysergic acid diethylamide (LSD) microdosing in people experiencing depression (LSDDEP2)
• The Influence of Psychedelics on Fundamental Beliefs and Mental Health
• Safety, tolerability, pharmacokinetics, pharmacodynamics and exploratory efficacy of intravenous dosing of SPL026 drug product (N, N-dimethyltryptamine fumarate; DMT Fumarate [A Serotonergic Psychedelic]) alone or in combination with selective serotonin reuptake inhibitors in patients with major depressive disorder
• Safety, blood levels and effects of N,N-dimethyltryptamine [DMT (SPL026)] in healthy participants that have taken psychedelic substances before (Part A) and in healthy participants with little to no psychedelic experience (Part B)
• Psilocybin TRD Feasibility RCT
• The Impact of Psilocybin on Pain in Fibromyalgia Patients (PsiloFM)
• Psilocybin-Assisted Cognitive Processing Therapy for Chronic PTSD
• Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD
• Psilocybin for Treatment-Resistant Depression
• Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults
• The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
• Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression (TREK)
• Cancer Related Major Depression Treated With a Single Dose of Psilocybin (CAPSI)
• PsilOCD: A Pharmacological-Challenge Feasibility Study
• Psilocybin in Chronic Low Back Pain and Depression
• Characterization of the Temporal Profile of the Anti-nociceptive Effect of Ketamine Bolus Measured With ANI (Keta-ANI)
• The Effect of Esketamine on Sleep Disturbance
• Effect of Esketamine on Conscious State in Patients With pDoC
• Esketamine Treatment for Depressive Episodes With Suicidal Ideation in Mood Disorders
• Study of IV Ketamine for Emergency Department Treatment of Adolescent Suicidal Ideation (KSI)
• Ketamine for Veterans With Parkinson’s Disease (KPD)
• Dose Low Dose Ketamine in Casesarian
• Ketamine-assisted Psychotherapy for Adolescent PTSD (KAP)
• A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder (SOLEO)
• Safety, Tolerability, Analgesic Effect, and Feasibility of Intranasal CT001 in Pediatric Patients
• Observation of Safety and Tolerability Within 1 Year of the Use of R-ketamine /​ Placebo in Drug-resistant Depression
• Swinburne Three-dose Psilocybin Assisted Psychotherapy (3PAP): a clinical trial of 2 vs 3 doses of psilocybin-assisted psychotherapy vs psychotherapy with placebo for Treatment-Resistant Depression
• A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of up to Two Doses of Psilocybin for the Treatment of Major Depressive Disorder in Adults With Cancer
• Prosocial Effects of MDMA (PEM)
• Evaluation of Psilocybin-assisted Psychotherapy (PaP) for the Treatment of Post-traumatic Stress Disorder (PTSD) in Military Veterans
• Does Psilocybin Require Psychedelic Effects to Treat Depression? (PSI-RIS)
• A phase II randomized, double-blind, active placebo-controlled parallel group trial to examine the efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE)
• A randomised controlled trial of oral S-ketamine as add-on medication for patients with treatment-resistant major depressive disorder
• Clinical and neurobiological predictors of response to ketamine: towards personalized treatment of depression
• PSILOCD
• A study to investigate the effects of repeated low doses of psilocybin and ketamine on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action
• Can a one-off administration of psilocybin reduce alcohol intake in patients with alcohol use disorder? A randomized, double-blinded, placebo-controlled clinical trial
• Long-Term Safety and Persistence of Effectiveness of Manualized MDMA Assisted Therapy for the Treatment of Posttraumatic Stress Disorder
• Open-Label Proof of Concept Feasibility Study to Explore the Safety, Tolerability and Potential Role of MDMA-Assisted Psychotherapy for the Treatment of Detoxified Patients with Alcohol Use Disorder
• A double-blind, randomised trial of methylphenidate-assisted versus MDMA-assisted therapy for mood and anxiety symptoms in advanced-stage cancer patients
• Psilocybin-assisted psychotherapy for the treatment of depression and anxiety associated with life-threatening illness
• Investigating the impact of of Psilocybin and guided meditation on brain connectivity in healthy adults
• Brain Activity Effects of Psychedelic Medicines in Healthy Volunteers
• A Phase 1 Randomized, First-in-Human, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses of EMP-01 in Healthy Adult Volunteers
• Developing Optimal Psychedelic Assisted Psychotherapy: Investigating the Effect on Symptom Severity for Adults with Obsessive-Compulsive Disorder
• A study of the psychological, cognitive and physiological effects of Psychedelic Medicines on healthy individuals (ASSESS)
• MethAmphetamine use in young people: safety and tolerability of Sub-anaesthetic Ketamine, An Open-label Trial
• Safety and tolerability of psilocybin-assisted physiotherapy in healthy volunteers
• An open-label feasibility study of ketamine-assisted therapy in adults with treatment-resistant depression
• An Open-Label Feasibility Study to Assess the Safety and Effect of Manualised MDMA-Assisted Psychotherapy for the Treatment of Severe Posttraumatic Stress Disorder among Four Australians
• Evaluating the atittudes of Australian psychologists, psychiatrists and mental health researchers towards 3,4-Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for the treatment of PTSD: A double-blind, randomised controlled trial
• Resistant Depression – Ketamine Infusion Trial Evaluation
• Ketamine-ECT Study
• Can a low dose of ketamine change how people with treatment-resistant depression remember their lives, deal with emotions, and make decisions?
• An open-label clinical trial of oral ketamine, an NMDA (N-methyl-D-aspartate) receptor antagonist, with weekly dosing over six weeks, in 25-50 patients who are experiencing chronic suicidal ideation.
• A dose-finding and proof-of-concept study of the efficacy and safety of MSP-1014.OX in patients with major depressive disorder
• Ketamine-assisted psychological therapy to reduce alcohol relapse
• A longitudinal open-label, dose-ranging clinical trial to evaluate the effectiveness of oral ketamine, an NMDA (N-methyl-D-aspartate) receptor antagonist, in patients who are experiencing chronic suicidal ideation
• An open-label, dose ranging, clinical trial of oral ketamine, an NMDA (N-methyl-D-aspartate) receptor antagonist, with weekly dosing over six weeks in patients who are experiencing post-traumatic stress disorder (PTSD)
• Study of Ketamine for Youth Depression
• Proof of concept study for evaluation of the effect of ketamine intranasal spray in treatment of chronic Cluster Headache (CCH)
• Investigation of antidepressant efficacy of oral ketamine treatment
• The Role of mTOR (Mammalian Target of Rapamycin) Signaling Pathway in the Antidepressive Effect of Ketamine in Patients with Depressive Disorder
• A multicentre, double-blind, randomised, placebo – controlled phase II study to assess efficacy, safety and pharmacokinetics of inhaled Esketamine in subject with treatment-resistant depression in the course of Major Depressive Disorder
• A randomised, double blind, active placebo-controlled crossover trial to evaluate the short term efficacy of an N-Methyl-D-Aspartate antagonist for patients with treatment resistant depression
• Effect of ketamine on anxiety ratings in patients with anxiety disorders
• Effectiveness of ketamine therapy among patients with treatment-resistant depression: a double-blind, randomised, controlled trial
• Enhancing Week-long Psychological Treatment for PTSD With Ketamine
• A Study of Different Oral Thin Film (S)-Ketamine Formulations for Sublingual Administration in Healthy Participants
• Phase 1 Bioavailability Study of MELT-100 (Midazolam and Ketamine Sublingual) and IV Midazolam or Ketamine
• Ketamine for the Treatment for Alcohol Use Disorder in the ED
• Psilocybin in Adults With and Without Autism Spectrum Disorder (PSILAUT)
• MDMA and memory
• A study into the safety and effects of psychotherapy in combination with MDMA as a treatment for severe post-traumatic stress disorder
• The incidence of hyponatremia in people using MDMA
• A randomised, placebo controlled trial of psilocybin in treatment resistant depression: A feasibility study
• Efficacy of intranasal ketamine on acute suicidality, a double blind randomized placebo-controlled trial (Ketamine Trial Amsterdam, KETA)
• Ketamine in treatment resistant major depression (TRD)
• Phase I Open-label Study of Low-dose Ketamine Infusion Treatment in Levodopa-Induced Dyskinesia in Parkinson’s Disease
• Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS)
• Effects of Ketamine on Mentalizing and Metacognition in Healthy Volunteers
• Glutamate Emotion Memory Study
• Ketamine for the Treatment of Depression in Parkinson’s Disease
• Evaluation of Safety, Rate and Extent of Absorption of Psilocin Mucate (Psilocin-1)
• Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment
• Add-on Therapy With Edupression.Com® on Therapy Resistant Depressive Patients Treated With Nasal Esketamine Spray
• Ketamine Assisted Psychotherapy for Opioid Use Disorder
• The Effect of Ketamine on Aesthetics and Role for Antidepressant Effects
• Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial
• Ketamine-enhanced Prolonged Exposure Therapy in PTSD
• Effect of Esketamine on Depressive Symptoms of Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy
• Oral ketamine as an additional treatment in patients with treatment-resistant depression
• Neural Circuit Effects of Ketamine in Depression
• Testing the Effectiveness of Cognitive Training Among Depressed Patients Receiving Esketamine Treatment
• Effect of Esketamine on Depressive Symptoms of Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy (EDSOP)
• Mystical Experience in Hypnosis: a Neurophenomenological Study (MystHyp)
• Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention (ENDURE)
• Repeated Neurocognitive Measurements in Depressed Patients
• Ketamine + Cognitive Training for Suicidality in the Medical Setting
• Effect of Ketamine and Etomidate During RSI on Long Term Outcomes (RSI-LTO)
• Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine
• Role Of Non-Specific Effects in The Treatment of Depression With Esketamine (ROSETTE)
• Examining Mu Opioid Mechanisms of Ketamine’s Rapid Effects in OCD (MKET2) (MKET2)
• PSIL201 Long-term Follow-up Study: Psilocybin or Niacin /​ Major Depressive Disorder
• Adding Trauma-focused Psychotherapy to Ketamine Treatment for Chronic PTSD
• KAP for Depression in Abstinent Opioid Users (KReDO)
• Tolerance and Potential Synergistic Effect of the Combination of Intranasal Esketamine and Non-selective MAOI (ESKETAM)
• Ketamine and Neurofeedback-Training: Effects on Neuroplasticity in Cocaine Addiction (Co-Boost)
• Effect of Esketamine on Postoperative Depression, Gut Microbiota, Bispectral Index Data of Depression Patients Undergoing Breast Cancer Operation (ESPOD-BI) (ESPOD-BI)
• Assessing the Efficacy of Micro-dosed Psilocybin on Reducing Anxiety & Depression Levels in Adults
• Ketamine Low dOse Evaluation on Morphine Consumption in Traumatic Patient (KLOE)
• Ketamine Infusion for Rapid Reduction of Suicidality in Pediatrics (Keta4SI)
• The Perinatal Synergistic Multi-component Intervention to alLeviate dEpressive Symptoms. A Case Series (SMILES)
• Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects (LBL)
• A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD
• The Effectiveness of Continuous Ketamine Infusion (KONTINUE)
• Low-Dose Intravenous Ketamine for Adolescents With Depression and Suicidal Ideation in the Emergency Department
• Impact of Ketamine On Depressive Symptoms In Patients Undergoing Lumbo-peritoneal Shunt Insertion
• Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan (REaKT-SD)
• Effects of LSD on Neuroplasticity in Healthy Subjects
• [11C]-(R)-Rolipram to Measure cAMP Signaling Before and After Ketamine
• Neural Correlates of Ketamine’s Anti-suicidal Effects in Bipolar Depression (DEEPP)
• Ketamine Enhances Analgesia and Mood in Chronic Pain Patients
• Long Term Follow Up KET-PD
• The Effect of a Four Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. (INTENSIFY MDD)
• The Effects of Sedatives on Tobacco Use Disorder Version 2 (SED-TUD2)
• KET-RO Plus RO DBT for Treatment Resistant Depression (KET-RO)
• Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy
• Psilocybin Therapy for Chronic Low Back Pain
• The Anesthetic Ketamine as Treatment for Patients With Severe Acute Brain Injury
• Ketamine in Severe Traumatic Brain Injury
• Naturalistic Study of Ketamine in the Treatment of Depression
• Ketamine in Acute Brain Injury Patients
• Glutamatergic Mechanisms of Psychosis and Target Engagement (SA1)
• The Impact of AMPA Receptor Blockade on Ketamine’s Anti-Suicidal Effects
• Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine
• A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide (ASPIRE I)
• Group MDMA-therapy for Veterans With PTSD (Group-MVP)
• A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of up to Two Doses of Psilocybin for the Treatment of Major Depressive Disorder in Adults With Cancer
• VA Aripiprazole vs Esketamine for Treatment Resistant Depression (VAST-D II)
• A clinical trial of Psilocybin-assisted psychotherapy as a treatment for anorexia nervosa
• Phase I psilocybin safety trial
• Psychedelic Therapy for Wellness Studies Retrospectively
• Psilocybin in Functional Neurological Disorder (PsiFUND)
• A study of the psychological, cognitive and physiological effects of Psychedelic Medicines (ASSESS)
• MDMA Plus Exposure Therapy for PTSD
• A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression (SUSTAIN-2)
• The Effect of LSD on Neural Synchrony, Prosocial Behavior, and Relationship Quality
• An Open-Label, Single Dose Study in Patients With Alcohol Use Disorder
• Developing Optimal Psychedelic Assisted Psychotherapy for Obsessive-Compulsive Disorder
• Inpatient Single Dose Interventions for Alcohol Use Disorder
• Repeated Intranasal Esketamine Plus Almond Therapy in Participants With Treatment Resistant Depressive Disorder – 3 Month Extension Study (ZYL-730-02)
• Belief Updating in Treatment Resistant Depression
• A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD) With Depressive Symptoms
• Reversal of Battle-Related Aging (ROBRA) in a Special Operations Forces Cohort
• Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure (INTENSIFY)
• Study of Harmine in Healthy Subjects
• LSD-Perceptual-Choice-Study
• LSD to Improve Cluster Headache Impact Trial
• LSD microdosing
• Psilocybin as a tool for enhancing cognitive flexibility
• The effects of three small morning and evening doses of LSD on mood, biological and psychological measures of sleep, neuroplasticity, and well-being
• Pharmacokinetic-pharmacodynamic modeling of S(+)-ketamine in healthy volunteers
• LSD microdosing – A repeated dosing study
• MDMA for Co-occurring PTSD and OUD After Childbirth
• Social Anxiety MDMA-Assisted Therapy Investigation
• MDMA-assisted Therapy for Fibromyalgia
• Epigenetics and MDMA-Assisted Psychotherapy for PTSD
• MDMA-assisted Massed Prolonged Exposure for PTSD
• Prosocial Effects of MDMA
• Perceptions of MDMA-Assisted Therapy Among Veterans With PTSD
• Does Serotonin System Stimulation Increase Pro-social Behavior? – A Comparative Pharmacological Neuroscientific Study in Healthy Humans
• Modified Ketogenic Diet and Ketamine for Anorexia Nervosa
• Intramuscular Ketamine for Suicidal Ideation
• The Effectiveness and Safety of Esketamine in Modified Electroconvulsive Therapy
• A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant Depression
• Psilocybin in the Treatment of Cannabis Use Disorder: A-Proof-of-Concept Study
• Comparison of Ketamine and Esketamine in Patients Suffering From Fibromyalgia Syndrome
• ECT vs. Esketamine
• IM and IV SPL026 Drug Product in Healthy Participants
• Multi-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headaches
• Esketamine for the Treatment of Rett Syndrome
• Effects of Esketamine on Postpartum Depression
• An EEG Study of Intravenous Ketamine for Major Depression Disorder
• A Single Ketamine Infusion Combined With Music for Suicidal Ideation
• Esketamine on Postpartum Depression in Cesarean Section Women
• Study of IV Ketamine for Emergency Department Treatment of Adolescent Suicidal Ideation
• Maintenance Ketamine Infusions for Treatment-Resistant Bipolar Depression
• Ketamine-assisted Psychotherapy (KAP) for Patients With Existential Distress Associated With Non-operable GI Cancers
• Ketamine and Stress in OCD
• Using Virtual Reality to Control the Audio-visual Inputs During Ketamine/Esketamine Treatment
• A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression
• Qualitative Study About Psychedelics Using in Psychiatric Disorders (PSYCHEQUALI)
• Ketamine for Adult Depression Study (KADS)
• The Efficacy of Ibogaine in the Treatment of Addiction; an open label, single fixed dose pilot-study of the efficacy of ibogaine in opioid-dependent subjects
• Sub(acute) Profiling of 2C-B Versus Psilocybin
• A Trial of GH001 in Patients With Treatment-resistant Depression
• Safety and Tolerability of DMT in Healthy Adults
• BPL-003 Efficacy and Safety in Treatment Resistant Depression
• Safety, Tolerability and Antidepressant Effects of DMT in Patients With Depression
• Effects of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) administered by intramuscular injection on frequency oscillatory power bands in healthy adults
• Interactions between 3,4-methylenedioxymethamphetamine (MDMA or ’ecstasy’) and Ä9-tetrahydrocannabinol (THC or ‘marihuana’) in humans
• A Double-Blind Randomised Controlled Trial of the Efficacy of Microdosing with Psilocybin to treat Moderate Depression
• Investigating the safety, feasibility and acceptability of psilocybin-assisted psychotherapy in treatment resistant depression
• An open label study to investigate the safety and feasibility of delivering 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy to patients with posttraumatic stress disorder
• Effectiveness of Psychedelic Therapy for Treatment Resistant Depression (TRD)
• Effectiveness Of Psychedelic Therapy for Post Traumatic Stress Disorder (PTSD)
• Ketamine versus Ketamine plus Behavioural Activation Therapy for Adults with Treatment Resistant Depression
• A clinical trial to assess safety and efficacy of psilocybin-assisted psychotherapy for treatment-resistant anorexia nervosa in adults
• An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1)
• Efficacy and safety of two versus three high dose psilocybin-assisted therapy sessions in comparison to a placebo for treatment resistant major depressive disorder (TR-MDD): A double blind, 3-arm Phase 2b randomised controlled trial
• The role of 5-HT2 and 5-HT1A receptors in 3,4-methylenedioxymethamphetamine (MDMA) induced memory impairment and impulsivity.
• Can memantine prevent memory impairment induced by MDMA in humans.
• MDMA, Cortisol and Memory
• Come closer: a neurobiological analysis of the prosocial effects of MDMA
• Evaluating the Positioning of Esketamine Treatment (PoET) for symptom management in adults with major depressive disorder
• The role of the 5-HT2a receptor in MDMA-induced effects on social cognition and prosocial behaviour
• Effects of alcohol (0.5 %0) and MDMA (100 mg) on (simulated) driving performance, driving related performance and traffic safety
• Effect of SSRIs on Response to Psilocybin Therapy
• MDMA-assisted Brief Cognitive Behavioral Conjoint Therapy for PTSD (MDMA-bCBCT)
• Dose-finding PKPD Trial for RE02 in Healthy Subjects
• Functional, cognitive and behavioural effects of 5-MeO-DMT administered by intramuscular injection
• Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder (PAP-AUD)
• Psilocybin in Cancer Pain Study
• PARTING: Psilocybin-Assisted suppoRtive psychoTherapy IN the treatment of prolonged Grief
• Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects (LBL)
• Treatment Resistant Depression Intervention with Psilocybin-assisted Psychotherapy
• A study to investigate the safety and feasibility of delivering MDMA-assisted psychotherapy to patients with posttraumatic stress disorder
• LSD-Perceptual-Choice-Study (LUCY)
• A Phase 1, Single Centre, Randomised, Double Blind, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NeuroDirect Ketamine in Healthy Adult Volunteers
• The Effect of Transcranial Magnetic Stimulation and Oral Ketamine Combination Treatment on severity of symptoms in Post-Traumatic Stress Disorder (TMS-OK PTSD)
• An open-label clinical trial of oral ketamine, an NMDA (N-methyl-D-aspartate) receptor antagonist on depressive symptomatology in people aged 16 years and older who are experiencing treatment-resistant depression
• A Phase 2 Open-Label Treatment Development Study of MDMA-Assisted Cognitive Processing Therapy (CPT) for Posttraumatic Stress Disorder (PTSD)
• MDMA-Assisted CBCT for PTSD vs CBCT RCT
• Preliminary Effectiveness of Individual and Group MDMA-assisted Therapy for Israeli Veterans With PTSD and Moral Injury
• Comparing Mescaline Sodium Enteric-coated Tablets vs Morte-mescaline in the Treatment of Adult Lupus Nephritis
• MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other
• Sustaining Remission From PTSD Using Tuned Vibroacoustic Stimulation (TVS) Following MDMA-Assisted Psychotherapy
• Ayahuasca Assisted Psychotherapy for Grief
• Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use Disorder
• Acute Analgesic Effects of DMT on Experimentally Induced Pain in Healthy Participants
• An open-label study of the efficacy and feasibility of psilocybin-assisted psychotherapy for treatment-resistant depression (TRD)
• A pilot study to test the effects of a single microdose of ayahuasca alkaloids on blood pathology of neurotransmitters and inflammation marker levels, safety observations, and mood self-efficacy in healthy adults
• A Randomised, Double-Blind, Active Placebo-Controlled Phase 2 Pilot Study of MDMA-Assisted Manualised Psychotherapy in Australian War Veterans with Chronic, Treatment-Resistant Posttraumatic Stress Disorder (PTSD)
• Studying the antidepressant effects of intravenous ketamine in patients with major depressive disorder
• MDMA (3,4-methylenedioxy-N-methylamphetamine) for the treatment of tinnitus
• A Community of Practice Program With Psilocybin-assisted Therapy for End-of-Life Patients
• LSD Occupancy of the Serotonin 2A Receptor in the Human Brain (dOccLS)
• A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide (ASPIRE II)
• A Dose-Ranging Study of 50 µg to 100 µg LSD in Healthy Volunteers
• Psilocybin as a model of psychotic illness
• Pre-post Evaluation of the Safety and Efficacy of Ibogaine-Magnesium Therapy in Veterans With Repeated Blast Exposure
• A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/​Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder (ESCAPE-TRD)
• Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder (BIPOD-In)
• Drug Effects on Interpersonal Interaction
• MDMA for AUD/​PTSD Comorbidity (MDMA)
• A randomised, double-blind, placebo-controlled trial to study the effects of repeated microdoses of lysergic acid diethylamide (LSD) on creativity and brain activity in healthy adult males
• A dose-finding and proof-of-concept study of the efficacy and safety of MSP-1014.OX in patients with major depressive disorder
• Exploratory trial to assess the efficacy and safety of Psilocybin-Assisted Psychotherapy (PAP) involving family-members compared to standard PAP, in adults with treatment-resistant major depressive disorder. (TRMDD)
• Lysergic Acid Diethylamide (LSD) in Palliative Care (LPC)
• Delix Therapeutics Phase I Trial for Novel Compound DLX-001
• Assessing the effects of Lysergic acid diethylamide (LSD) microdosing in people experiencing depression (LSDDEP1)
• A feasibility study of Psychedelic Microdosing-Assisted Meaning Centred Psychotherapy in advanced stage cancer patients (PAM Trial)
• Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer
• 2C-B vs psilocybin Maastricht Study
• Phase I psilocybin safety trial ATMA
• Phase 2 Clinical Trial of GH001 in Bipolar II Disorder
• MDMA-assisted Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder
• LUCID-201-001: A Double-Blind, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Lucid-201
• An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome
• Dose-finding Study for the Combination of DMT and Harmine in Healthy Subjects (DHTP)
• A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
• MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder
• Mindfulness and Psychedelics
• Tolerability of MDMA in Schizophrenia (TMS)
• Safety and Pharmacokinetics of GH002 in Healthy Volunteers
• Abuse Potential and Human Pharmacology of Methylone
• Neural and Physiological Correlates of Psychedelic Sub-states (i2)
• Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers
• Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects (DMT BDR-Study) (DMT BDR)
• A Phase III Trial Investigating the Effects of Ketamine-Assisted Therapy in the Treatment of Alcohol Use Disorder
• Animal and human serotonergic model of schizophrenia: validity evaluated by qEEG and fMRI
• Effects of MDMA on memory when witnessing or committing a simulated crime
• PET Synaptogenesis After Psilocybin In DEpression Recovery (PET-SPIDER)
• An open label study to evaluate the safety, tolerability, and subjective effects of two dimethyltryptamine (DMT) and harmala alkaloid containing formulations in healthy volunteers
• A study in healthy volunteers to look at how COMP360 is taken up by the body when given as two different strength capsules
• A study on the safety and effects of the drug DMT in healthy smoking individuals
• Consciousness and Psilocybin Effects on Well-Being: Pilot Phase (CoPE Pilot)
• Assessing the subjective intensity of oral psilocybin in patients with treatment-resistant depression: A Pilot Study (PSILODEP-PILOT)
• Psilocybin-assisted Interpersonal and Social Rhythm Therapy for Depression
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of KUR-101 in Healthy Adults
• Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD (COMP 006)
• Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD (COMP005)
• Clinical Study of DMT in Healthy Adults
• The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy Training (TherPsySE)
• Safety and Tolerability of Psilocybin in Post-Traumatic Stress Disorder
• Effects of Psilocybin in Obsessive Compulsive Disorder
• Psilocybin for the Treatment of Veterans With Post-Traumatic Stress Disorder
• PAPR: PAP + MBSR for Front-line Healthcare Provider COVID-19 Related Burnout (PAPR)
• Effects of Psilocybin in Concussion Headache
• Single and Repeat Doses of DMT in Healthy Subjects
• Psilocybin in Patients With Fibromyalgia: EEG-measured Brain Biomarkers of Action (Psilopain)
• SPL026 With or Without SSRIs in Participants With MDD
• Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects (2C-B)
• Personality and Drug Use (PDU)
• Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain
• Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study
• An Evaluation of Psilocybin’s Effect on Cardiac Repolarization
• Minidosing Lysergic Acid Diethylamide (LSD) for Chronic Cluster Headache
• LSD Treatment for Persons With Alcohol Use Disorder (LYSTA)
• Bioavailability Study of Psilocybin in Normal Adults
• MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers
• 5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder
• ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression
• Psilocybin-assisted Psychotherapy for Treatment of Alcohol Use Disorder
• Psilocybin-assisted Therapy for Treatment of Alcohol Use Disorder
• A Dose-Finding Study of MM-120 for the Treatment of Anxiety Symptoms
• Pragmatic Trial of Psilocybin Therapy in Palliative Care (PT2PC)
• Psilocybin Therapy in Advanced Cancer
• Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder
• Microdosing Psilocybin for Depression
• KRN-101 for Cancer-Related Distress
• Safety and efficacy of psilocybin-assisted psychotherapy for Generalised Anxiety Disorder [Psi-GAD-1]: a randomised triple-blind active-placebo-controlled trial
• A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder
• Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Function (MASM)
• Psilocybin Versus Ketamine in Treatment-Resistant Depression (PSIKET_001)
• Acute Dose-dependent Effects of DMT in Healthy Subjects: A Placebo-controlled Cross-over Study (DMT DR)
• The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD
• Effects of Repeated Psilocybin Dosing in OCD
• Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia
• Single Ascending Dose Study With BPL-003 in Healthy Subjects
• An Open-Label, Phase 2, Feasibility Study of Manualized MDMA-Assisted Psychotherapy in Subjects with Major Depressive Disorder
• Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder
• Comparing the Effects of Psilocin and Psilocybin in Healthy Adults
• The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
• Effects of Psilocybin in Post-Treatment Lyme Disease
• Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating Disorder
• Acute Effects of R- and S-MDMA in Healthy Subjects (R-S-MDMA)
• Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain
• Microdosing Psychedelics to Improve Mood
• Mood and Cognitive Effects of Psilocybin in Healthy Participants (MELO)
• Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder
• Psilocybin as a tool for enhancing cognitive flexibility
• Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid Use
• Ketamine as an Adjunctive Therapy for Major Depression (KARMA-dep)
• Exploratory Study of Low Dose Psilocybin
• Psilocybin-assisted CBT for Depression
• Palliadelic Treatment to Reduce Psychological Distress in Persons With Inoperable Pancreatobiliary Cancer
• The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation
• Safety and Efficacy of Low Dose MM-120 for ADHD Proof of Concept Trial
• Neuronal Correlates of Altered States of Consciousness (5HT2A-fMRI)
• Ketamine for Reduction of Alcoholic Relapse (KARE)
• Effects of SERT Inhibition on the Subjective Response to LSD in Healthy Subjects (SERT-LSD)
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression (TRANSFORM-3)
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression (TRANSFORM-2)
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression (TRANSFORM-1)
• Study of Feasibility and Safety of MDMA-Assisted Group Therapy for the Treatment of PTSD in Veterans (MPG1)
• Pharmacokinetics of GH001 in Healthy Volunteers
• Frontline Clinician Psilocybin Study
• Naturalistic Study of Microdosing With Psilocybin (NATMICRO)
• Food Effects on Bioavailability of MDMA in Healthy Volunteers (MPKF)
• Social Anxiety MDMA-Assisted Therapy Investigation (SAMATI)
• Psilocybin-facilitated Treatment for Chronic Pain
• Psilocybin Therapy for Depression and Anxiety in Parkinson’s Disease (PDP)
• A Study of Oral Ibogaine in Opioid Withdrawal
• Evaluation of Psilocybin (TRP-8802) to Decrease Hyperphagia
• Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia
• Effect of Ketamine on Neurological Activity as Measured by Electroencephalogram (EEG)
• Psilocybin Therapy for Depression in Bipolar II Disorder (BAP)
• Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care
• A Treatment Development Study of MDMA-Assisted Psychotherapy for PTSD
• Psilocybin for Treatment-Resistant Depression
• Long-Term Safety and Effectiveness of Manualized MDMA-Assisted Therapy for the Treatment of Posttraumatic Stress Disorder
• Exploring Medically Perceived Benefits, Use and Interest in Psychedelics and Cannabinoids
• Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder
• Entheogen Resurgence
• Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia
• Lophora LPH-5 Phase Ia Safety Trial
• MYND MYND-604 Phase Ia Safety Trial
• Field Trip FT-104 Phase Ib Safety Trial
• BetterLife Pharma TD-0148A Phase I
• Field Trip FT-104 Phase IIa Trial
• Field Trip FT-104 Phase IIb Trial
• Low Dose Ketamine Infusion for the Treatment of Resistant Depression
• Effect of Lithium Versus Placebo in Adults With Treatment-Resistant Depression Who Are Receiving Ketamine
• Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma
• Ketamine for Preventing Depression in Patients Undergoing Treatment for Pancreatic or Head and Neck Cancers
• Ketamine for Major Depressive Disorder
• The Role of HNKs in the Antidepressant Effect of Ketamine
• A Multi-site Expanded Access Program for MDMA-assisted Psychotherapy for Patients With Treatment-resistant PTSD
• A Study to Assess 18-Methoxycoronaridine (18-MC HCl) in Healthy Volunteers
• Low-dose S-Ketamine and Postpartum Depression in Parturients With Prenatal Depression
• Adjunctive Effects of Psilocybin and Buprenorphine
• Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer’s Disease
• Comparative Acute Effects of LSD, Psilocybin and Mescaline
• Effect of Ketanserin After LSD Administration
• A Study of HR071603 (Ketamine Nasal Spray) in Healthy Subjects
• Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans
• A Study of Psilocybin for Major Depressive Disorder (MDD)
• Ketamine Alcohol (in Treatment-Resistant Depression)
• Psychedelics and Wellness Study (PAWS)
• Low-dose S-ketamine in Women With Prenatal Depression
• Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
• NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression
• LSD Therapy for Persons Suffering From Major Depression
• Circulating Oxytocin Changes in Response to the Oxytocin System Stimulator MDMA in Patients With Diabetes Insipidus and Healthy Controls
• Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder
• A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD
• A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide
• Intraoperative Ketamine Versus Saline in Depressed Patients Undergoing Anesthesia for Non-cardiac Surgery
• Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study
• Behavioral and Electrophysiological Effects of Ketamine in Treatment-Resistant Depression
• Ketamine Interleaved With Electroconvulsive Therapy for Depression
• Nitrous Oxide for the Treatment of Major Depressive Disorder
• Effects of Psilocybin in Anorexia Nervosa
• Ketamine or Placebo in Patients With Major Depression and Advanced Cancer
• THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis
• Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study
• The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression
• LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders
• Prophylactic Effects of Psilocybin on Chronic Cluster Headache
• Phase 1b Study in Patients With Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)
• Ketamine for the Treatment of Opioid Use Disorder and Depression
• Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder
• Esketamine and Perioperative Depressive Symptoms
• Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)
• Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification
• Ketamine Versus Electroconvulsive Therapy in Depression
• Mechanism of Action Underlying Ketamine’s Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
• Pilot RECAP Study in Healthy Normal Volunteers
• Ketamine Long Therm Follow Up Study
• Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
• Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
• Use of Transmucosal Ketamine in Post Stroke Depression
• Ketamine for Older Adults Pilot
• Psilocybin – Induced Neuroplasticity in the Treatment of Major Depressive Disorder
• The Effects of MDMA on Prefrontal and Amygdala Activation in PTSD
• Effects of MDMA-like Substances in Healthy Subjects
• Long-term Observation of Participants With Mood Disorders
• MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function
• Psilocybin for Treatment of Alcohol Use Disorder: a Feasibility Study
• Repeat Dosing of Psilocybin in Migraine Headache
• The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density
• Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department
• A Phase I Randomized, Placebo Controlled, Double-Blind, Single-Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of PCN-101 (Arketamine) and a Relative Safety Comparison of PCN-101 and Esketamine in Healthy Volunteers
• A Double-blind, Placebo-controlled Study to Evaluate Very Low Dose LSD in Healthy Volunteers Aged 55-75 Years
• Direct Comparison of Altered States of Consciousness Induced by LSD and Psilocybin
• Effects of Salvinorin A on Brain Function
• Rapid Antidepressant Effects of Ketamine in Major Depression
• Role of the Serotonin 5-HT2A Receptor in LSD-induced Altered States of Consciousness (LDR-Study)
• Low-dose Ketamine and Postpartum Depression in Parturients With Prenatal Depression
• A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)
• Safety of GH001 in Healthy Volunteers
• Biomarkers of Response to Ketamine in Depression: MRI and Blood Assays Before and After Open Label Intranasal Ketamine
• Effect of Ketamine in Depressive Symptoms of Elderly Patients With Visual Impairment
• Effectiveness of Ketamine for Depression and Suicidal Ideation in the Emergency Department
• Low Dose Intravenous Ketamine in Treatment Resistant Depression Patients
• Evaluation of MDMA on Startle Response
• Mood Effects of Serotonin Agonists Extended
• Study of Oral Ketamine Versus Placebo for Treating Depression in Patients Undergoing Treatment for Cancer
• Ketamine and Nitroprusside for Depression
• A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)
• Sequential Therapy for the Treatment of Severe Bipolar Depression
• miRNAs, Suicide, and Ketamine – Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome
• Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy
• Bristol Imperial MDMA in Alcoholism Study
• Micro-Dose, Macro-Impact: Leveraging Psychedelics in Frontline Healthcare Workers During the COVID-19 Pandemic
• Study of Ketamine for Depression in Cancer Patients Receiving Palliative Care
• Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Psychotherapy for Treatment of PTSD
• Open Label Ketamine Treatment for Major Depressive Disorder in Veterans
• Effect of Methylenedioxymethamphetamine (MDMA) (Serotonin Release) on Fear Extinction
• Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine
• Music as an Intervention to Improve Hemodynamic Tolerability of Ketamine in Depression
• Effect of Low-dose Esketamine on Postoperative Depression in Patients With Breast Cancer
• SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients
• IM Ketamine vs Midazolam for Suicidal ER Patients
• ELE-LSD as a potential treatment for Alzheimer’s Disease
• PEX010, a psilocybin formulation for potential treatment of MDD
• ELE-Ket+ for MDD
• CYB001 to evaluate as a potential treatment for Major Depressive Disorder
• Single Ascending Dose Study With 5-MeO-DMT in Healthy Subjects
• A Randomized, Double-Blind, Single Ascending Dose Study to Identify a Safe and Non-Psychedelic Dose of Psilocybin
• PEX010 PEX020 PEX030
• Mescaline for AUD
• Ayahuasca Tea
• Ibogaine HCl (DMX-1002) for OUD
• Phase IIb, a double-blind, placebo-controlled clinical trial to investigate the safety and efficacy of MDMA-assisted psychotherapy for Alcohol Use Disorder
• Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe OCD
• Open-label safety, tolerability and proof-of-concept study investigating the potential role for MDMA-Assisted Psychotherapy in treating patients with alcohol use disorder
• Psilocybin (MYCO-001) for PTSD in Veterans
• DMX-NB1 as a potential treatment of Opioid Use Disorder
• AP-188 DMT being developed as a possible treatment of ischemic stroke and for post-stroke rehabilitation
• Ibogaine in the Treatment of Alcoholism: a Randomized, Double-blind, Placebo-controlled, Escalating-dose, Phase 2 Trial
• Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer
• Psilocybin for Psychological and Existential Distress in Palliative Care
• Repeated Neurocognitive Measurements in Depressed Patients
• Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers (MT-2)
• Precision Functional Brain Mapping in Psilocybin
• A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD
• Effects of Dimethyltryptamine in Healthy Subjects
• LSD Base and LSD Tartrate Bioequivalence and Bioavailability in Healthy Subjects
• Study Comparing Two Versus Three Active MDMA-assisted Sessions in U.S. Military Veterans With Chronic PTSD
• Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy
• Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study
• Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of Consciousness
• Stanford Reward Circuits of the Brain Study – MDMA
• A Multi-Site Study of MDMA-Assisted Psychotherapy for Eating Disorders
• Esketamine Adjuvant Therapy for Patients With Chronic Visceral Pain Comorbid Major Depressive Disorder
• Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents
• Visual Surround Suppression and Perceptual Expectation Under Psilocybin
• Field Trip FT-104 Phase Ia Safety Trial
• Reward Emotion Learning and Ketamine Study
• Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression
• The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.
• An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)
• Pilot Trial of Visual Healing in Psilocybin-assisted Therapy for Alcohol Use Disorder
• Preoperative Ketamine and Perioperative Depression
• Effects of MDMA Co-administration on the Response to LSD in Healthy Subjects
• MDMA-Assisted Psychotherapy in Veterans With Combat-Related, Refractory PTSD
• Pharmacogenetics Associated With IV Ketamine
• Ketamine to Prevent PPD After Cesarean
• Ketamine Treatment Effects on Synaptic Plasticity in Depression
• An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
• Clinical and Mechanistic Effects of Psilocybin in Alcohol Addicted Patients
• University of Iowa Interventional Psychiatry Service Patient Registry
• Intravenous Ketamine Effects on Functional Neuroanatomy
• Neurodynamics of Prosocial Emotional Processing Following Serotonergic Stimulation With N,N-Dimethyltryptamine (DMT) and Harmine in Healthy Subjects
• Imaging Neural Correlates of Ketamine Using PET/MR
• The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder
• Opiate Suicide Study in Patients With Major Depression
• The Effect of S-ketamine for Patients Undergoing Electroconvulsive Therapy (ECT)
• An Observational Pre-post Study Evaluating the Safety of Tabernanthe Iboga Exposure
• Study to Assess the Effects of Intranasal Ketamine Along With rTMS for Patients With Treatment-resistant Major Depressive Disorder (TRD)
• A Two-Year Observational Follow-up Study of Subjects With Major Depressive Disorder Following a Randomized, Double-Blind Single-Dose of Psilocybin or Niacin-Control
• Clinical Study of GH001 in Depression
• Clinical, Neurocognitive, and Emotional Effects of Psilocybin in Depressed Patients – Proof of Concept
• Assessing the Pharmacokinetics and Drug Interaction Liability of Kratom, an Opioid-like Natural Product
• Effects of Drugs on Responses to Brain and Emotional Processes
• Ketamine IV Classic Protocol : Five Years Follow up
• Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression
• Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms
• A Naturalistic Study of Ketamine for Treatment Resistant Mood Disorders
• Effects of SERT Inhibition on the Subjective Response to Psilocybin in Healthy Subjects
• Efficacy And Tolerability Of Sub-Anesthetic Ketamine In Postpartum Depression
• Chart Review of Patients Undergoing Ketamine Infusions
• Ketamine Associated ACC GABA and Glutamate Change and Depression Remission
• Ketamine Infusion Therapy for the Treatment of PTSD in Paramedics
• Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache
• Psilocybin for Treatment of Obsessive Compulsive Disorder
• Single-dose Ketamine for the Reduction of Pain and Depression in the Emergency Department
• NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation
• Role Of Ketamine in Treatment-Resistant Major Depressive Disorder And Its Effect on Suicidality
• CYB001 tolerability in healthy participants
• EEG Characteristics in ECT
• Endogenous Opioid Modulation by Ketamine
• Ketamine for Mood Disorders With Suicidal Ideation
• The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
• Using a Low Dose of Ketamine vs. Active Placebo in Treating Severe Depression and Suicide
• Study of Safety and Effects of MDMA-assisted Psychotherapy for Treatment of PTSD
• Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors
• Intramuscular Ketamine Versus Aripiprazole and Escitalopram in the Treatment of Resistant Depression (KETProject)
• Ketamine Co-induction for Patients With Major Depressive Disorder
• Evaluation of Schemes of Administration of Intravenous Ketamine in Depression
• Ketamine for Treatment Resistant MDD
• Psilocybin and Depression
• Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine
• Mood Effects of Serotonin Agonists
• Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse
• Effects of Psilocybin in Major Depressive Disorder
• ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)
• Ketamine and Postoperative Depressive Symptom-PASSION
• The Neurobiological Effect of 5-HT2AR Modulation
• Intravenous Ketamine Plus Neurocognitive Training for Depression
• Psilocybin for the Treatment of Migraine Headache
• ECT With Ketamine Anesthesia vs High Intensity Ketamine With ECT Rescue for Treatment-Resistant Depression
• Persisting Effects of Psilocybin
• The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.
• The Impact of Ketamine on the Reward Circuitry of Suicidal Patients
• Role of Dopamine, Serotonin and 5-HT2A Receptors in Emotion Processing
• Cognitive Therapy to Sustain the Antidepressant Effects of Intravenous Ketamine in Treatment-resistant Depression
• Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
• The UTHealth Ketamine Project
• Psilocybin for the Treatment of Cluster Headache
• MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD
• Hyperventilation Combined With Etomidate or Ketamine Anesthesia in ECT Treatment of Major Depression
• Double-Blind Trial of Ketamine Therapy Plus or Minus Naltrexone in Treatment Resistant Depression (TRD)
• A Study to Decrease Suicidal Thinking Using Ketamine
• Emergency Ketamine Treatment of Suicidal Ideation
• Physiological and Cognitive Biomarkers for Ketamine’s Antidepressant Effects
• D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression
• Effect of Stimulant Drugs on Social Perception
• Positron Emission Tomography Assessment of Ketamine Binding of the Serotonin Transporter
• Naltrexone Plus Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder
• Imaging SV2A in Mood Disorders
• Cognitive Recovery After Electroconvulsive Therapy and General Anesthesia
• Intra-nasal vs. Intra-venous Ketamine Administration
• Examining the Impact of Sirolimus on Ketamine’s Antidepressant Effects
• Ketamine Anesthesia for Improvement of Depression in ECT
• Ketamine for Depression: An MRI Study
• Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression
• Effects of Low Dose Ketamine Given at Induction of Anesthesia on Postoperative Mood in Patients With Depressive Symptoms
• Ketamine for Relapse Prevention in Recurrent Depressive Disorder
• Ketamine Infusion for Adolescent Depression and Anxiety
• Effects of Low-dose Ketamine as an Adjunct to Propofol-based Anesthesia for Electroconvulsive Therapy
• Ketamine for Treatment Resistant Late-Life Depression
• Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive Disorder
• Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression
• Intranasal Ketamine for Late-Life Depression and Suicidal Ideation
• Spreading Depolarization and Ketamine Suppression
• Psilocybin-facilitated Treatment for Cocaine Use
• Ketamine Infusions for PTSD and Treatment-Resistant Depression
• Ketamine for Depression Relapse Prevention Following ECT
• MDMA-assisted Psychotherapy for Anxiety Associated With a Life-threatening Illness
• Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression
• The Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Religious Professionals
• Ketamine Trial for the Treatment of Depression
• Effects of Psilocybin-facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion
• The Role of 5-HT2A Receptor in the Perception of Self and Personal Meaning in Healthy Volunteers
• Cognitive Behavioral Therapy in Prolonging the Antidepressant Effects of Intravenous Ketamine
• Ketamine as an Alternative Treatment to ECT in Major Depressive Disorder
• Effect of Subanesthetic Dose of Ketamine Combined With Propofol on Cognitive Function in Depressive Patients Undergoing Electroconvulsive Therapy
• Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder
• A Multimodal Neuroimaging Study of Brain Activation Patterns Under Ketamine
• Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)
• Effects of MDMA on Emotional and Social Memories
• Ketamine for Depression and Suicide Risk
• Abuse Liability and Human Pharmacology of Mephedrone
• Ketamine’s Actions on Rumination Mechanisms as an Antidepressant
• Ketamine in Adolescents With Treatment-Resistant Depression
• Ketamine Infusions for Major Depression Disorder
• Effect of the Addition of Ketamine to Sevoflurane Anesthesia in Electroconvulsive Therapy
• Biomarkers of Fast Acting Therapies in Major Depression
• UW Psilocybin Pharmacokinetics Study
• A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence
• Clinical Trial of the Use of Ketamine in Treatment Resistant Depression
• Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators
• Effects of Hallucinogens and Other Drugs on Mood and Performance
• A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive Disorder
• Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults
• Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression
• Ketamine Use in Electroconvulsive Therapy
• The Effect of Ketamine on Mechanises Underlying Suicidal Ideation and Drug-resistant Major Depression
• Exploring Mechanisms of Action in MDMA-assisted Psychotherapy for PTSD
• Ketamine as a Rapidly-Acting Antidepressant in Depressed Emergency Department Patients
• Beyond the Self and Back: Neuropharmacological Mechanisms Underlying the Dissolution of the Self
• Effects of Methylphenidate, Modafinil, and MDMA on Emotion-processing in Humans: A Pharmaco-fMRI Study
• Ketamine for Treatment-resistant Depression: A Multicentric Clinical Trial in Mexican Population
• Ketamine for Suicidality in Bipolar Depression
• Randomized, Double-blind, Controlled of MDMA-assisted Psychotherapy in 12 Subjects With PTSD
• Comparing Ketamine and Propofol Anesthesia for Electroconvulsive Therapy
• Ketamine Plus Lithium in Treatment-Resistant Depression
• Examining The Effect Of Ketamine On Glutamate/Glutamine Cycling
• An Open Prospective Trial of IV Ketamine in Suicidal Adolescents
• The Effect of Minocycline on Relapse After Successful Intravenous Ketamine/Minocycline-induced Symptoms Response in Subjects With Depression
• Psychological, Physiological, Endocrine, and Pharmacokinetic Effects of LSD in a Controlled Study
• Action of Ketamine in Treatment-Resistant Depression
• Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators
• Randomized, Double-blind, Active Placebo-Controlled Pilot Study of MDMA-assisted Psychotherapy in People With Chronic PTSD
• NMDA Antagonists in Bipolar Depression
• Trial of Ketamine and Lithium Therapy in Bipolar Depression
• Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder
• Influence of Bupropion on the Effects of MDMA
• A Study of Ketamine in Patients With Treatment-resistant Depression
• Nitrous Oxide as Treatment for Major Depression – a Pilot Study
• Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD
• Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer
• Effects of MDMA and Methylphenidate on Social Cognition
• Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder
• Ketamine in the Treatment of Suicidal Depression
• PET Imaging of mGLuR5 With Drug Challenge
• Treatment of Suicidal Ideation With Intravenous Ketamine Infusion
• Ketamine Infusion for Treatment-resistant Major Depressive Disorder
• Treatment Resistant Depression (Pilot)
• Ketamine for Depression and Alcohol Dependence
• Estimate the Efficiency of the Association of an Injection of Ketamine and the Venlafaxine in the Severe Major Depressive Disorder for Six Weeks
• Study of Ketamine as an Antidepressant in Major Depressive Disorder
• Ketamine in the Treatment of Depression
• Effects of Sevoflurane and Ketamine on QT in Electroconvulsive Therapy
• Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence
• Ketamine For Suicidal Ideation
• Subanesthetic IV Bolus Ketamine in the Treatment of Acute Depression
• Emotional Effects of Methylphenidate and MDMA in Healthy Subjects
• Additional MDMA-assisted Psychotherapy for People Who Relapsed After MDMA-assisted Psychotherapy Trial
• Intranasal Ketamine in Treatment-Resistant Depression
• Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers
• Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA)
• Ketamine Anesthesia in Electroconvulsive Therapy
• The Use of Ketamine as an Anaesthetic During Electroconvulsive Therapy
• Neuromodulation to Facilitate the Effect of Ketamine
• Pharmacological Interaction Between Carvedilol and Methylenedioxymethamphetamine (MDMA)
• Naturalistic Study Into the Hangover Effects of MDMA
• N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression
• Study Comparing Three Doses of MDMA Along With Psychotherapy in Veterans With Posttraumatic Stress Disorder
• Effects of MDMA on Social and Emotional Processing
• Pharmacological Interaction Between Clonidine and Methylenedioxymethamphetamine (MDMA)
• Study of Depression-Ketamine-Brain Function
• Ketamine as an Augmentation Strategy for Electroconvulsive Therapy (ECT) in Depression
• Use of Ketamine to Enhance Electroconvulsive Therapy (ECT) in Depression
• Ketamine for Low Mood States in the ER
• Study of the Effects of MDMA/Ecstasy on Water Regulation, Sleep, and Cognition.
• Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female Subjects
• Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy)
• Psilocybin and Spiritual Practice
• Treatment Study of Bipolar Depression
• Placebo Controlled Study of Sublingual Salvinorin A
• Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine: Pharmacodynamics (PD) and Pharmacokinetics (PK)
• Role of Serotonin in Acute and Subacute MDMA Effects
• Psilocybin Cancer Anxiety Study
• Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD)
• Effects of Salvinorin A in Healthy Controls
• Human Psychopharmacology of Salvinorin A
• Optimization of IV Ketamine for Treatment Resistant Depression
• Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study
• Ketamine Frequency Treatment for Major Depressive Disorder
• Lysergic Acid Diethylamide (LSD)-Assisted Psychotherapy in People With Illness-related Anxiety
• Randomized Placebo-controlled Study of MDMA-assisted Psychotherapy in People With PTSD – Israel
• Continuation Ketamine in Major Depression
• Psychopharmacology of Psilocybin in Cancer Patients
• MDMA-assisted Therapy in People With Anxiety Related to Advanced Stage Cancer
• Research Study for Major Depressive Disorder: Investigation of Glutamate Medications
• Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress Disorder
• Investigation of Serotonin Neurotransmission in MDMA Users Using Combinated Dexfenfluramine Challenge and PET Imaging
• Functional Brain Imaging in Recreational Users of Ecstasy
• Neurobiology and Pharmacokinets of Acute MDMA Administration
• Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety
• A Test of MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder
• Methylenedioxymethamphetamine (MDMA, Ecstasy) Induced Changes in Drug Metabolism: Gender and Genetic Polymorphisms
• The NeXT Study
• Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine)